PRINCETON, N.J., Nov. 15, 2017 /PRNewswire/ -- Promius Pharma LLC announced today that ZEMBRACE ® SymTouch ® (sumatriptan injection) 3 mg, an acute migraine headache treatment on the market since ...

Dr. Reddy's Laboratories (NYSE: RDY), announced today that the U.S. Food and Drug Administration (FDA) has approved ZEMBRACE™SymTouch™ (sumatriptan succinate) injection, a drug-device combination ...

Subcutaneous sumatriptan 6 mg is undeniably an excellent treatment of migraine. However, some patients have avoided using 6 mg sumatriptan because of unpleasant or unwanted side effects. To evaluate ...

Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...

MUMBAI, Feb 17 (Reuters) - Drug firm Wockhardt Ltd on Tuesday said it will be launching Sumatriptan injections in the U.S. following following final approval from the U.S. Food & Drug Administration.

Expert Rev Clin Pharmacol. 2013;6(3):271-288. Triptans are highly effective for short-term treatment of acute migraine attacks. They are effective in MA or MO, but are not intended for use in ...

Strategic Acquisition Helps Build Tonix’s Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Management of Fibromyalgia Acquisition of Zembrace® SymTouch® ...

Strategic Acquisition Helps Build Tonix’s Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Treatment of Fibromyalgia Acute Migraine Products Complement ...